Findings

What do systematic reviews say?

254 questions · 269 findings · 31 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 34 · 12.6%GRADE not reported 3 · 1.1%Very low 70 · 26%Low 93 · 34.6%Moderate 44 · 16.4%High 25 · 9.3%

Omega‐3 vs placebo

Memory ‐ not measured · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease

Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
RR 1.05 [0.78, 1.41]
1 study · 402 participants
High

Omega‐3 vs placebo

QoL · Apathy in people with mild‐to‐moderate Alzheimer's disease

2 findings from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Moderate
Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 332 participants
High

Omega‐3 vs placebo

Depressive symptoms · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 178 participants
High

Omega‐3 vs placebo

Mental health outcomes · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 543 participants
High

Omega‐3 vs placebo

Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease

2 findings from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 566 participants
High
Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 202 participants
High

Omega‐3 vs placebo

IADL · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

Intervention not reported

Standardised tests of reading, writing, spelling or mathematics skills (overall) · children with specific learning disorders

The review found no eligible studies for this question.

1 finding from 1 review

Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse effect (gastrointestinal disturbance) · children with specific learning disorders

The intervention showed no clear difference in adverse effect (gastrointestinal disturbance) (low certainty).

1 finding from 1 review

Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders 2016 · Cochrane Headline outcomes only
RR 1.43 [0.25, 8.15]
2 studies · 116 participants
Low

Higher vs lower PUFA

All allergic disease ‐ Infancy (incidence) · infants

It is very uncertain whether higher changes all allergic disease ‐ infant incidence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.96 [0.73, 1.26]
1 study · 323 participants
Very low

Higher vs lower PUFA

All allergic disease ‐ childhood prevalence · infants

It is very uncertain whether higher changes all allergic disease ‐ childhood prevalence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.98 [0.81, 1.19]
2 studies · 633 participants
Very low

Higher vs lower PUFA

Asthma ‐ childhood prevalence · infants

It is very uncertain whether higher changes asthma ‐ childhood prevalence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 1.12 [0.82, 1.53]
2 studies · 635 participants
Very low

Higher vs lower PUFA

Dermatitis/eczema ‐ childhood prevalence · infants

It is very uncertain whether higher changes dermatitis/eczema ‐ childhood prevalence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.81 [0.59, 1.09]
2 studies · 635 participants
Very low

Higher vs lower PUFA

Allergic rhinitis ‐ childhood prevalence · infants

It is very uncertain whether higher changes allergic rhinitis ‐ childhood prevalence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 1.02 [0.83, 1.25]
2 studies · 635 participants
Very low

Higher vs lower PUFA

Food allergy ‐ childhood prevalence · infants

It is very uncertain whether higher changes food allergy ‐ childhood prevalence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.27 [0.06, 1.19]
1 study · 119 participants
Very low

Higher vs lower PUFA

Asthma ‐ Infancy (incidence) · infants

Higher showed no clear difference in asthma ‐ infant incidence compared with lower PUFA intake (low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 1.04 [0.8, 1.35]
3 studies · 1162 participants
Low

Higher vs lower PUFA

Eczema ‐ Infancy (incidence) · infants

It is very uncertain whether higher changes dermatitis/eczema ‐ infant incidence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.93 [0.82, 1.06]
7 studies · 1906 participants
Very low

Higher vs lower PUFA

Allergic rhinitis ‐ infant incidence · infants

It is very uncertain whether higher changes allergic rhinitis ‐ infant incidence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.47 [0.23, 0.96]
2 studies · 594 participants
Very low

Higher vs lower PUFA

Food allergy ‐ Infancy (incidence) · infants

It is very uncertain whether higher changes food allergy ‐ infant incidence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.81 [0.56, 1.19]
3 studies · 915 participants
Very low

Higher vs lower PUFA

All allergic disease ‐ childhood (incidence) · infants

It is very uncertain whether higher changes all allergic disease ‐ childhood incidence compared with lower PUFA intake (very low certainty).

1 finding from 1 review

Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy 2016 · Cochrane Headline outcomes only
RR 0.69 [0.47, 1.02]
2 studies · 154 participants
Very low